- $128.21m
- -$54.56m
Brief: Nkarta Inc Files For Mixed Shelf Of Up To $350 Million - SEC Filing
Brief: Nkarta Reports Fourth Quarter And Full Year 2022 Financial Results And Corporate Highlights
Nkarta Inc reports results for the quarter ended in December - Earnings Summary
Brief: Nkarta Q4 net loss USD 32.6 million
Nkarta Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Nkarta Promotes David R. Shook M.D. To Chief Medical Officer
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba
U.S. STOCKS ON THE MOVE-TFF Pharma, BioRestorative,
U.S. STOCKS ON THE MOVE-Energy firms, Nkarta, Domino's Pizza
Nkarta gains on positive data from lymphatic cancer therapy trial
Brief: Nkarta Announces Updated Clinical Data On Anti-CD19 Allogeneic CAR-NK Cell Therapy NKX019 For Patients With Relapsed Or Refractory Non-Hodgkin Lymphoma
Nkarta Inc reports results for the quarter ended in September - Earnings Summary
Brief: Nkarta Reports Third Quarter 2022 Financial Results
Brief: Nkarta Presents Data Supporting Engineered NK Cell Based Combination Therapies
Nkarta Inc expected to post a loss of 62 cents a share - Earnings Preview
Nkarta Inc reports results for the quarter ended in June - Earnings Summary
Brief: Nkarta Inc - As Of June 30, 2022, Nkarta Had Cash, Cash Equivalents, Restricted Cash, And Short-Term Investments Of $415.0 Million
Nkarta Inc expected to post a loss of 59 cents a share - Earnings Preview
Nkarta Inc reports results for the quarter ended in March - Earnings Summary